This study was designed to determine the incidence and severity of gastrointestinal (GI) side effects in patients taking erythromycin. More patients complained of GI side effects with the enteric-coated tablet (70.8 percent) than with the stearate (51.4 percent) or the ethylsuccinate (48.9 percent) salts. The enteric-coated tablet was associated with a higher incidence of individual adverse reactions; more patients discontinued it because of adverse GI effects. These data demonstrate a high incidence of GI side effects to erythromycin. Additionally, GI side-effect incidence appears to be higher with the enteric-coated tablet.
CarterBLHellingDKJonesMEFriedmanRLEllsworthA.Multicenter study of family physician prescribing.J Fam Pract1984; 19: 497–501.
2.
KuderHV.Propionyl erythromycin. A review of 20,525 case reports for side effect data.Clin Pharmacol Ther1960; 1: 604–9.
3.
GriffithRSBlackHR.Erythromycin.Med Clin North Am1970; 54: 1199–215.
4.
ShansonDCTidburyPMcnabbWRTadayonM.The pharmacokinetics and tolerance of oral erythromycin stearate compared with erythromycin ethylsuccinate: implications for preventing endocarditis.J Antimicrob Chemother1984; 14: 157–63.
5.
BowieWRManzonLMBorrie-HumeCJFawcettAJonesHD.Efficacy of treatment regimens for lower urogenital Chlamydia trachomatis infection in women.Am J Obstet Gynecol1982; 142;125–8.
6.
BrownSTPedersenAHBHolmesKK.Comparison of erythromycin base and estolate in gonococcal urethritis.JAMA1977; 238: 1371–3.
7.
PutziRBlaserJLuthyRWehrliRSiegenthalerW.Side-effects due to the intravenous infusion of erythromycin lactobionate.Infection1983; 11: 161–3.
8.
KlikaLJGoodmanJM.Gastrointestinal tract symptoms from intravenously administered erythromycin (letter).JAMA1982; 248;1309.
9.
MarlinGEThompsonPJJenkinsCRBurgessKRLafranierDAJ.Study of serum levels, venous irritation and gastrointestinal side-effects with intravenous erythromycin lactobionate in patients with bronchopulmonary infections.Hum Toxicol1983; 2: 593–605.
10.
MeadeRHIIIDrug therapy reviews: antimicrobial spectrum, pharmacology, and therapeutic use of erythromycin and its derivatives.Am J Hosp Pharm1979; 36: 1185–9.
11.
JanickiRSGarnhamJCWorlandMCGrundyWEThomasJR.Comparison of erythromycin ethylsuccinate, stearate and estolate treatments of group A streptococcal infection of the upper respiratory tract.Clin Pediatr1975; 14: 1098–107.
12.
BoggianoBGGleesonM.Gastric acid inactivation of erythromycin stéarate in solid dosage forms.JPharm Sci1976; 65: 497–502.
13.
WellingPCHuangHHewettPFLyonsLL.Bioavailability of erythromycin stéarate: influence of food and fluid volume.J Pharm Sci1978; 67: 764–6.
14.
ItohZSuzukiTNakayaMInoueMMitsuhashiS.Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut.Antimicrob Agents Chemother1984; 26: 863–9.
15.
SinghYNHarveyALMarshallG.Antibiotic induced paralysis of the mouse phrenic nerve-hemidiaphragm preparation, and reversibility by calcium and by neostigmine.Anesthesiology1978; 48: 418–24.
